dupilumab   Click here for help

GtoPdb Ligand ID: 7574

Synonyms: Dupixent® | REGN668 | SAR231893
Approved drug Immunopharmacology Ligand
dupilumab is an approved drug (EMA & FDA (2017))
Compound class: Antibody
Comment: Dupilumab is fully human monoclonal antibody against the α subunit of the IL4 receptor.
Peptide sequences for this antibody are available from its IMGT/mAb-db record. Dupilumab was produced using Regeneron's genetically engineered VelocImmune® mice which have humanized immunoglobulin gene loci and produce human:mouse hybrid antibodies that can rapidly be converted to fully human antibodies [3].
Click here for help
Immunopharmacology Comments
Dupilumab inhibits IL-4 and IL-13 (two cytokines that promote inflammation and which are elevated in patients with atopic dermatitis and asthma) binding to the shared receptor alpha subunit, interleukin-4 receptor subunit α. This action prevents IL-4 and IL-13 from activating downstream pro-inflammatory pathways and relieves the symptoms of the targeted diseases.
Immunopharmacology Disease
Disease X-Refs Comment References
Atopic dermatitis Disease Ontology: DOID:3310
OMIM: 603165
Dupilumab is approved to treat atopic dermatitis (eczema).
Asthma Disease Ontology: DOID:2841
OMIM: 600807
Approved drug for asthma (FDA approval in October 2018).